Price Alert

Solid Biosciences Inc. (SLDB)

NASDAQ: SLDB · Real-Time Price · USD

5.90

0.16 (2.79%)

At close: Oct 03, 2025, 3:59 PM

5.99

1.53%

After-hours: Oct 03, 2025, 07:17 PM EDT

2.79% (1D)

Bid	5.75
Market Cap	459.43M
Revenue (ttm)	3.12M
Net Income (ttm)	-154.08M
EPS (ttm)	-2.65
PE Ratio (ttm)	-2.23
Forward PE	-2.99
Analyst	Buy
Dividends	n/a

Ask	5.99
Volume	1,178,030
Avg. Volume (20D)	1,200,846
Open	5.80
Previous Close	5.74
Day's Range	5.76 - 6.01
52-Week Range	2.41 - 7.37
Beta	2.54
Ex-Dividend Date	n/a

About SLDB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SLDB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SLDB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+10.6%

Solid Biosciences shares are trading higher after ... Unlock content with Pro Subscription

2 months ago

+8.51%

Solid Biosciences shares are trading higher after the company announced it received FDA Fast Track Designation status for SGT-501 gene therapy.

News

1 week ago · businesswire.com

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

SEATTLE--(BUSINESS WIRE)--Kinea Bio Inc., a biotechnology company dedicated to developing transformative genetic medicines, today announced two major achievements in its gene therapy program: a commit...

1 month ago · seekingalpha.com

Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference Transcript

Solid Biosciences Inc. (NASDAQ:SLDB ) Citi's Biopharma Back to School Conference September 2, 2025 1:45 PM EDT Company Participants Alexander Cumbo - President, CEO & Director Conference Call Particip...

2 months ago · seekingalpha.com

Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)

Solid Biosciences is approaching key catalysts in DMD gene therapy, with SGT-003 showing promising early safety and efficacy signals. The evolving DMD landscape, especially safety concerns with compet...